News

Article

NeurologyLive® Friday 5 — July 12, 2024

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending July 12, 2024.

Welcome to NeurologyLive®'s Friday 5! Every week, the staff compiles 5 highlights of NeurologyLive®'s widespread coverage in neurology, ranging from newsworthy study findings and FDA action to expert interviews and peer-to-peer panel discussions.

1: FDA Action Update, June 2024: Approvals, Designation, and Clearance

The FDA was busy in June 2024, making a number of decisions on potential new therapeutic agents including granting approvals, a designation, a clearance, an acceptance of application, a recommendation, and issuing a complete response letter.

FDA Action Update, June 2024: Approvals, Designation, and Clearance

2: NeurologyLive® Clinician of the Month Spotlight: Marisa McGinley, DO

As part of our monthly clinician spotlight, NeurologyLive® highlighted multiple sclerosis expert Marisa McGinley, DO, the staff neurologist at Cleveland Clinic’s Mellen Center for MS.

NeurologyLive® Clinician of the Month Spotlight: Marisa McGinley, DO

3: The Unexpected Maestro: How AI Is Composing a New Future for Dementia Care

Neal K. Shah, CEO of CareYaya Health Technologies, discussed the groundbreaking potential of AI-powered music therapy in revolutionizing dementia care, offering personalized interventions that can improve quality of life.

The Unexpected Maestro: How AI Is Composing a New Future for Dementia Care

4: NeuroVoices: Kelly Papesh, DNP, APRN, FNP-BC, on Understanding Patient Silence for Movement Disorder Concerns in the Clinical Setting

The executive director of the Association of Movement Disorder Advanced Practice Providers talked about a recent survey highlighting why patients with movement disorders may withhold critical health information from their providers.

NeuroVoices: Kelly Papesh, DNP, APRN, FNP-BC, on Understanding Patient Silence for Movement Disorder Concerns in the Clinical Setting

5: Broad FDA Approval of Gene Therapy Expands Treatment Choices for Duchenne Muscular Dystrophy: Debra Miller & Michael Kelly, PhD

The chief executive officer and the chief scientific officer at CureDuchenne talked about a recent webinar that discussed the broad FDA approval of a gene therapy for Duchenne muscular dystrophy, highlighting patient choice and the ongoing efforts to improve treatments. [WATCH TIME: 9 minutes]

Broad FDA Approval of Gene Therapy Expands Treatment Choices for Duchenne Muscular Dystrophy: Debra Miller & Michael Kelly, PhD

Newsletter

Keep your finger on the pulse of neurology—subscribe to NeurologyLive for expert interviews, new data, and breakthrough treatment updates.

Related Videos
Anna Pace, MD
Kristyn Pocock, MD
Dementia expert James Galvin, MD, MPH, a professor of neurology at the University of Miami Miller School of Medicine, and chief scientific officer at CogniVue
Rami Burstein, PhD
Michael Kaplitt, MD, PhD
2 experts are featured in this series.
2 experts are featured in this series.
© 2025 MJH Life Sciences

All rights reserved.